Clinical Validation and the Importance of Muscle Mass
Decades of research underscore the critical role of muscle mass in maintaining mobility and functional independance and reducing health risks.
Clinical Validation
MAT has been validated in adults of all ages. The MAT is currently being used to determine the effects of low muscle mass on health related outcomes in large cohort studies such as the Framingham Heart Study and the Women’s Healthcare Initiative.
Proven associations of MAT muscle mass with walking speed, strength and incident risk of hip fracture, disability, and mortality have also been established and published in longitudinal clinical studies.
Why Muscle Mass Matters:
Low muscle mass directly contributes to mobility disability in older adults, reducing independence and quality of life.
A diagnosis of low muscle mass in a patient with mobility disability will allow a healtcare professional to focus treatment on therapies for muscle mass.
Exclusion of low muscle mass in a patient with mobility disability will allow a healthcare professional to focus diagnostic work-up and therapies on alternative causes of mobility disability symptoms, such as poor balance, neurological problems, cognitive impairment, arthritis, poor vision, orthostatic hypotension, anemia, thyroid disease, limitations due to heart failure, peripheral vascular disease, pain, respiratory disease, obesity or fatigue.
Unlike lean mass, muscle mass is strongly linked to functional health outcomes.
We will list all of the publications using the MAT in clinical studies.
